Candidate secreted biomarkers for XXXX detection.

@entity1 @entity263 @entity5 @entity1067 @entity1486
UNASSIGNED: 9736 Background: Evaluation of @entity1486 ( @entity1486 ) is the current screening method for early detection of @entity263 . @entity1486 is more prostate specific than @entity5 specific, and elevated @entity1486 can also be found in benign conditions of the prostate. Thus, in spite of the overall success of @entity1486 screening, there is a continued need for more sensitive and specific methods for early detection of @entity263 . METHODS: We have developed an antibody-based approach to biomarker discovery in @entity5 , focusing on differential protein expression, using: i) a large collection of high affinity polyclonal antibodies raised against individual @entity1 proteins and their isoforms; ii) a proprietary multiplex protein array immunoassay, namely the matrix protein array technology (MPAT), coupled to a readout and data analysis system, and iii) clinical samples (tissue and serum) from normal, @entity1067 ( @entity1067 ), early and @entity263 @entity1 . Protein extracts from specimens were printed onto a membrane, then allowed to interact with 20,000 individual antibodies from our collection. Antibody-sample reaction was detected by chemiluminescence, and quantified by computer analysis of a CCD-acquired image, followed by statistical analysis. RESULTS: In the screening of tissue specimens we have identified three distinct panels of antibodies, specific for @entity5 , @entity263 , respectively. In addition, screening of 150 serum samples revealed antibody panels discriminating @entity5 . We have further characterized these biomarkers by western blot analysis. CONCLUSIONS: These biomarkers offer potential applications in the early diagnosis of @entity263 , and discrimination from benign conditions of the prostate. [Table: see text].
